The benzyl-substituted unbridged titanocene bis-[(p-methoxybenzyl)cyclopentadienyl] titanium(IV) dichloride (Titanocene Y) was tested in vitro against human renal cancer cells (Caki-1), in which it showed an IC 50 value of 36 ¾ 10 -6 mol/l. Titanocene Y was then given in vivo in doses of 10, 20, 30, 40 and 50 mg/kg on 5 consecutive days to Caki-1-bearing mice, and it showed concentration-dependent and statistically significant tumor growth reduction with respect to a solvent-treated control cohort. The maximum tolerable dose of Titanocene Y was determined to be 40 mg/kg and it showed significantly better tumor volume growth reduction than cisplatin given at a dose of 2 mg/kg. This superior activity of Titanocene Y with respect to cisplatin will hopefully lead to clinical tests against metastatic renal cell cancer in the near future.
Introduction
Despite the resounding success of cisplatin and closely related platinum anti-tumor agents, the movement of other transition metal anti-cancer drugs towards the clinic has been exceptionally slow [1] [2] [3] . Metallocene dichlorides (Cp 2 MCl 2 ) with M = Ti, V, Nb and Mo show remarkable anti-tumor activity [4, 5] . Unfortunately, the efficacy of Cp 2 TiCl 2 in phase II clinical trials in patients with metastatic renal cell carcinoma [6] or metastatic breast cancer [7] was too low to be pursued. Very recently, more synthetic effort has been employed to increase the cytotoxicity of titanocene dichloride derivatives [8] [9] [10] [11] [12] . A novel method starting from titanium dichloride and fulvenes [13] [14] [15] [16] allows direct access to highly substituted ansa-titanocenes [17] [18] [19] [20] , i.e. titanocenes containing a carbon-carbon bridge. By using this method we have synthesized [1,2-di(cyclopentadienyl)-1,2-di-(4-N,N-dimethylaminophenyl)ethanediyl] titanium dichloride (Titanocene X), which has an IC 50 value of 2.7 Â 10 -4 mol/l when tested for cytotoxic effects on the LLC-PK cell line [21] . It was followed by reports about heteroaryl [22] and methoxyphenyl [23, 24] substituted ansa-titanocenes, which show similar IC 50 values. Our most cytotoxic ansa-titanocene [1,2-di(cyclopentadienyl)-1,2-bis(m-dimethoxyphenyl)ethanediyl] titanium dichloride (Titanocene Z) shows an IC 50 value of 2.1 Â 10 -4 mol/l when tested on the LLC-PK cell line [23] .
The cytotoxic effect was further increased by synthesizing the analogs of unbridged titanocenes by establishing a completely new synthetic route, which has been published recently [25] . Bis-[(p-methoxybenzyl)cyclopentadienyl] titanium(IV) dichloride (Titanocene Y), which has an IC 50 value of 2.1 Â 10 -5 mol/l when tested on the LLC-PK cell line, was synthesized from fulvene and super hydride (LiBEt 3 H) followed by transmetallation with titanium tetrachloride. The structures of the titanocenes are shown in Fig. 1 .
The anti-proliferative activity of Titanocene X, Y and Z was studied in 36 human tumor cell lines [26] , and in four freshly explanted human tumors using Titanocene X [27] . These in vitro and ex vivo experiments showed that prostate, cervical and renal cell cancers are prime targets for this novel class of titanocenes. This paper investigates the anti-proliferative effect of Titanocene Y against Caki-1 cells in vitro and in a Caki-1 xenograft model in vivo.
Materials and methods

Caki-1 cell tests
Caki-1 cells (ATCC HTB-46) are derived from a human clear cell carcinoma of the kidney. The cells were seeded in 96-well plates (5000 cells/well), and cultivated with McCoy's 5a medium and 10% FBS (Invitrogen, Karlsruhe, Germany). At 24 h after seeding, Titanocene Y dissolved in 0.1% DMSO or cisplatin dissolved in medium was added in a concentration range of 10 -4 to 10 -9 mol/l. The plates were cultivated for 4 days at 371C and 5% CO 2 . Then, a routine MTT assay [28] was performed and IC 50 values were determined. Each in-vitro assay was performed 3 times identically.
Caki-1 xenografts
For in vivo testing, 10 7 Caki-1 cells were injected s.c. to female NMRI:nu/nu mice (eight mice per group). Treatment was initiated when tumors had grown to a palpable size (5-6 mm diameter). Titanocene Y was dissolved in DMSO (final concentration 10%) and diluted with 0.5% Tween-80 in saline. It was injected i.p. in doses of 10, 20, 30, 40 or 50 mg/kg/day once daily for 5 consecutive days. One group of mice was treated with the solvent (negative control) and another group with cisplatin (Medac, Hamburg, Germany) at a dose of 2 mg/kg/day, i.e. at a dose that was determined to be of significant efficacy in other xenograft experiments (unpublished). Tumor size was measured with a caliper-like instrument. Tumor volumes, relative tumor volumes (relative to the first treatment day) and treated/control (T/C) values were calculated. Body weight and mortality of the mice were determined continuously during the experiments for an estimation of tolerability. Additionally, in one experiment blood from the retro-orbital venous plexus was taken at the end of the treatment cycle. Blood parameters were determined with a Coulter counter. Serum creatinine and blood urea nitrogen (BUN) were determined using automated methodology routinely used in the clinic.
Results and discussion
In-vitro cytotoxicity
The in-vitro cytotoxicity of Titanocene Y and cisplatin was determined in three independent experiments using the Caki-1 cell line. Mean IC 50 values were determined to be 36 ± 4 mmol/l for Titanocene Y and 1.6 ± 0.2 mmol/l for cisplatin ( Fig. 2) .
Renal cancer has already been determined prior to this experiment to be one promising target for the presented titanocene. In an extensive in-vitro test of the antiproliferative activity of different titanocenes in 36 human cancer cell lines, the most promising results could be obtained for renal cancer cell lines with a range of the IC 50 values from 47 to 120 mmol/l [26] . The best results were obtained for the renal cancer cell line RXF 1781L (IC 50 47 mmol/l), whereas the IC 50 value for cisplatin was 192 mmol/l. The Caki-1 cell line was not tested in the mentioned study, but the even lower IC 50 value underlines the very promising cytotoxic effect, especially in renal cancer cells.
In-vivo efficacy
Results of in-vivo experiments using Caki-1 xenografts can be seen in Table 1 . In the first experiment, four groups of eight mice each were treated i.p. with solvent or Titanocene Y at doses of 10, 20 or 30 mg/kg for 5 consecutive days. As shown in Fig. 3(A) , Titanocene Y induced a significant and dose-dependent inhibition of tumor growth with T/C values of 61, 49 and 40%, respectively. As no severe side-effects were observed in this experiment we increased the doses of Titanocene Y in a second experiment to 40 and 50 mg/kg, and added a group treated with cisplatin at a dose of 2 mg/kg/day as a positive control. T/C values of 42 and 39% were obtained in this second experiment with Titanocene Y (Fig. 3B ).
In the highest dose used (50 mg/kg/day) five out of eight mice died of toxicity, suggesting that the maximum tolerated dose is about 40 mg/kg/day. Severe body weight loss of 15 or 16% accompanied by diarrhea was observed in both mice cohorts treated with the two highest doses. Dead mice showed signs of inflammation in the gastrointestinal tract at autopsy.
No severe side-effects were noticed at non-lethal doses. The body weight loss was moderate; no influence on hematological (white blood cells, platelets) and renal toxicity-associated (creatinine, BUN) parameters was noticed.
The cisplatin dose used has shown significant anti-tumor efficacy in other xenografts (personal observations). However, it cannot be excluded that the dose could be increased in the Caki-1 model, leading to higher toxicity and/or efficacy. Cisplatin revealed only a non-significant delay of tumor growth at the dose used; it had no significant influence on body weight or hematological and renal parameters. All in-vivo parameters are summarized in Table 1 .
Conclusion and outlook
The in-vitro experiments using Titanocene Y on the Caki-1 cell line resulted in a very promising cytotoxic effect with an IC 50 of 36 mmol/l, which represents a value in the significantly lower range of IC 50 values determined up to now for titanocenes on a broad panel of human cancer cell lines. The in-vivo experiments show that Titanocene Y induces a significant and dose-dependent inhibition of tumor growth with no severe side-effects for doses up to 30 mg/kg. In a second experiment with higher doses, a further inhibition of tumor growth was observed and a maximum tolerated dose of about 40 mg/kg/day was determined. No severe side-effects were noticed at non-lethal doses. These results have been compared with cisplatin, which was given at a dose of 2 mg/kg/day, but only a non-significant delay of tumor growth was observed.
This very promising Caki-1 mouse model should be a catalyst to promote Titanocene Y into a clinical phase I study against renal cell cancer in the near future.
